nach oben

Erschienen in:

24.08.2017 | Original Article

Management of superior vena cava syndrome in critically ill cancer patients

verfasst von: Sarah Morin, Adeline Grateau, Danielle Reuter, Eric de Kerviler, Constance de Margerie-Mellon, Cédric de Bazelaire, Lara Zafrani, Benoit Schlemmer, Elie Azoulay, Emmanuel Canet

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to describe the management and outcome of critically ill cancer patients with Superior Vena Cava Syndrome (SVCS).

Methods

All cancer patients admitted to the medical intensive care unit (ICU) of the Saint-Louis University Hospital for a SVCS between January 2004 and December 2016 were included.

Results

Of the 50 patients included in the study, obstruction of the superior vena cava was partial in two-thirds of the cases and complete in one-third. Pleural effusion was reported in two-thirds of the patients, pulmonary atelectasis in 16 (32%), and pulmonary embolism in five (10%). Computed tomography of the chest showed upper airway compression in 18 (36%) cases, while echocardiography revealed 22 (44%) pericardial effusions. The causes of SVCS were diagnosed one (0–3) day after ICU admission, using interventional radiology procedures in 70% of the cases. Thirty (60%) patients had hematological malignancies, and 20 (40%) had solid tumors. Fifteen (30%) patients required invasive mechanical ventilation, seven (14%) received vasopressors, and renal replacement therapy was implemented in three (6%). ICU, in-hospital, and 6-month mortality rates were 20, 26, and 48%, respectively. The cause of SVCS was the only factor independently associated with day 180 mortality by multivariate analysis. Patients with hematological malignancies had a lower mortality than those with solid tumors (27 versus 80%) (odds ratio 0.12, 95% confidence interval (0.02–0.60), p < 0.01).

Conclusion

Airway obstruction and pleural and pericardial effusions contributed to the unstable condition of cancer patients with SVCS. The vital prognosis of SVCS was mainly related to the underlying diagnosis.

Wilson LD, Detterbeck FC, Yahalom J (2007) Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 356(18):1862–1869. https://doi.org/10.1056/NEJMcp067190 CrossRefPubMed

Rice TW, Rodriguez RM, Light RW (2006) The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore) 85(1):37–42. https://doi.org/10.1097/01.md.0000198474.99876.f0 CrossRef

Carter BW, Erasmus JJ (2015) Acute thoracic findings in oncologic patients. J Thorac Imaging 30(4):233–246. https://doi.org/10.1097/RTI.0000000000000148 CrossRefPubMed

Khan UA, Shanholtz CB, McCurdy MT (2014) Oncologic mechanical emergencies. Emerg Med Clin North Am 32(3):495–508. https://doi.org/10.1016/j.emc.2014.04.001 CrossRefPubMed

Morikawa N, Honna T, Kuroda T et al (2005) Life-threatening airway obstruction caused by mediastinal germinoma in a 9-year-old girl. J Pediatr Surg 40(3):588–590. https://doi.org/10.1016/j.jpedsurg.2004.11.021 CrossRefPubMed

Jung B, Murgu S, Colt H (2011) Rigid bronchoscopy for malignant central airway obstruction from small cell lung cancer complicated by SVC syndrome. Ann Thorac Cardiovasc Surg 17(1):53–57CrossRefPubMed

Kvale PA, Simoff M, Prakash UBS, American College of Chest Physicians (2003) Lung cancer. Palliative care. Chest 123(1 Suppl):284S–311SCrossRefPubMed

Takeda S, Miyoshi S, Omori K, Okumura M, Matsuda H (1999) Surgical rescue for life-threatening hypoxemia caused by a mediastinal tumor. Ann Thorac Surg 68(6):2324–2326CrossRefPubMed

Marcy PY, Magné N, Bentolila F, Drouillard J, Bruneton JN, Descamps B (2001) Superior vena cava obstruction: is stenting necessary? Support Care Cancer 9(2):103–107CrossRefPubMed

10.

Thiéry G, Azoulay E, Darmon M et al (2005) Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol 23(19):4406–4413. https://doi.org/10.1200/JCO.2005.01.487 CrossRefPubMed

11.

Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22(7):707–710CrossRefPubMed

12.

Dizon DS, Krilov L, Cohen E et al (2016) Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 34(9):987–1011. https://doi.org/10.1200/JCO.2015.65.8427 CrossRefPubMedPubMedCentral

13.

Récher C, Coiffier B, Haioun C et al (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378(9806):1858–1867. https://doi.org/10.1016/S0140-6736(11)61040-4 CrossRefPubMed

14.

Azoulay E, Pène F, Darmon M et al (2015) Managing critically ill hematology patients: time to think differently. Blood Rev 29(6):359–367. https://doi.org/10.1016/j.blre.2015.04.002 CrossRefPubMed

15.

Zerbib Y, Rabbat A, Fartoukh M et al (2017) Urgent chemotherapy for life-threatening complications related to solid neoplasms. Crit Care Med 45(7):e640–e648. https://doi.org/10.1097/CCM.0000000000002331 CrossRefPubMed

16.

Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison DS (2015) Risk of critical illness among patients with solid cancers: a population-based observational study. JAMA Oncol 1(8):1078–1085. https://doi.org/10.1001/jamaoncol.2015.2855 CrossRefPubMed

17.

Darmon M, Vincent F, Camous L et al (2013) Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol 162(4):489–497. https://doi.org/10.1111/bjh.12415 CrossRefPubMed

18.

Stone MJ, Bogen SA (2012) Evidence-based focused review of management of hyperviscosity syndrome. Blood 119(10):2205–2208. https://doi.org/10.1182/blood-2011-04-347690 CrossRefPubMed

19.

Moreau A-S, Lengline E, Seguin A et al (2014) Respiratory events at the earliest phase of acute myeloid leukemia. Leuk Lymphoma 55(11):2556–2563. https://doi.org/10.3109/10428194.2014.887709 CrossRefPubMed

20.

Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383(9927):1503–1516. https://doi.org/10.1016/S0140-6736(13)61048-X CrossRefPubMed

21.

Schraufnagel DE, Hill R, Leech JA, Pare JAP (1981) Superior vena caval obstruction is it a medical emergency? Am J Med 70(6):1169–1174CrossRefPubMed

22.

de Kerviler E, Benet C, Brière J, de Bazelaire C (2012) Image-guided needle biopsy for diagnosis and molecular biology in lymphomas. Best Pract Res Clin Haematol 25(1):29–39. https://doi.org/10.1016/j.beha.2012.01.006 CrossRefPubMed

23.

Maxwell F, de Margerie MC, Bricout M et al (2015) Diagnostic strategy for the assessment of axillary lymph node status in breast cancer. Diagn Interv Imaging 96(10):1089–1101. https://doi.org/10.1016/j.diii.2015.07.007 CrossRefPubMed

24.

de Kerviler E, de Margerie-Mellon C, Coffin A et al (2015) The feasibility of percutaneous renal cryoablation under local anaesthesia. Cardiovasc Intervent Radiol 38(3):672–677. https://doi.org/10.1007/s00270-014-0995-x CrossRefPubMed

25.

de Margerie-Mellon C, de Bazelaire C, Amorim S et al (2015) Diagnostic yield and safety of computed tomography-guided mediastinal core needle biopsies. J Thorac Imaging 30(5):319–327CrossRefPubMed

26.

de Margerie-Mellon C, de Bazelaire C, de Kerviler E (2016) Image-guided biopsy in primary lung cancer: why, when and how. Diagn Interv Imaging 97(10):965–972. https://doi.org/10.1016/j.diii.2016.06.016 CrossRefPubMed

27.

Porte H, Metois D, Finzi L et al (2000) Superior vena cava syndrome of malignant origin. Which surgical procedure for which diagnosis? Eur J Cardiothorac Surg 17(4):384–388CrossRefPubMed

28.

Urruticoechea A, Mesía R, Domínguez J et al (2004) Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer. Lung Cancer 43(2):209–214CrossRefPubMed

29.

Qanadli SD, El Hajjam M, Mignon F et al (1999) Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents. AJR Am J Roentgenol 173(1):159–164CrossRefPubMed

30.

Leung ST, Sung THT, Wan AYH, Leung KW, Kan WK (2015) Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting. Hong Kong Med J 21(5):426–434. 10.12809/hkmj144363 PubMed

31.

Smayra T, Otal P, Chabbert V et al (2001) Long-term results of endovascular stent placement in the superior caval venous system. Cardiovasc Intervent Radiol 24(6):388–394. https://doi.org/10.1007/s00270-001-0055-1 CrossRefPubMed

32.

Chan RC-L, Chan YC, Cheng SW-K (2013) Mid- and long-term follow-up experience in patients with malignant superior vena cava obstruction. Interact Cardiovasc Thorac Surg 16(4):455–458. https://doi.org/10.1093/icvts/ivs562 CrossRefPubMedPubMedCentral

33.

Bellefqih S, Khalil J, Mezouri I et al (2014) Superior vena cava syndrome with malignant causes. Rev Pneumol Clin 70(6):343–352. https://doi.org/10.1016/j.pneumo.2014.08.001 CrossRefPubMed

34.

Azoulay E, Mokart D, Pène F et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31(22):2810–2818. https://doi.org/10.1200/JCO.2012.47.2365 CrossRefPubMed

35.

Canet E, Zafrani L, Lambert J et al (2013) Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One 8(2):e55870. https://doi.org/10.1371/journal.pone.0055870 CrossRefPubMedPubMedCentral

36.

Lemiale V, Mokart D, Resche-Rigon M et al (2015) Effect of noninvasive ventilation vs oxygen therapy on mortality among immunocompromised patients with acute respiratory failure: a randomized clinical trial. JAMA 314(16):1711. https://doi.org/10.1001/jama.2015.12402 CrossRefPubMed

Titel: Management of superior vena cava syndrome in critically ill cancer patients
verfasst von: Sarah Morin
Adeline Grateau
Danielle Reuter
Eric de Kerviler
Constance de Margerie-Mellon
Cédric de Bazelaire
Lara Zafrani
Benoit Schlemmer
Elie Azoulay
Emmanuel Canet
Publikationsdatum: 24.08.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 2/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3860-z

Springer Medizin

Management of superior vena cava syndrome in critically ill cancer patients